The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
An LPS human challenge trial has been conducted over the past number of months, and recently completed with no serious adverse events – which is very positive to see. The full trial read-out of the unblinded data will be in Q2 2023.
POLB 001 has a long patent life, which is critical to pharma if they are to take the drug to phase III.
Investors are told to expect Data analysis and full data read-out is expected in Q2 2023. Investors appear to think the Company has kicked the can down the road. Yet, the board are in active discussions with potential license-out partners. Is it a case investor are playing it cautious due to the history of AIM Companies frequently being underwhelming?
Agree - I knew alot of that but very very good - i said before likely takeover! few months forward looking back here what a bargain 6.12p - Grant funding POLD003 other bits of update before the big news POLB001 Q2 - the share price will do same race ahead before at the moment sleeping
Any free shares for me?
It will all happen in 2023 - focus on the progress of the company not the poor share price 6p - am certain jeremy will top up again soon !
Cathal Friel -Spinning Poolbeg Pharma out of Hvivo (formerly known as Open Orphan) and getting Professor Luke O’Neill as non-executive director and scientific advisory board member changed everything. In my opinion, it is one of the most exciting and pivotal deals I’ll ever do, as I firmly believe Poolbeg Pharma could become a $1 billion pharmaceutical company.
It has a flu product which could help avoid future flu pandemics, oral vaccine technology, and an oral GLP-1 diabetes product which could become the most valuable obesity treatment in the world.
It also has the world’s largest repository of respiratory infectious disease progression data, and this data is invaluable for AI drug discovery programmes which Poolbeg is progressing.
jeremy skillington will probably buy more shares if this falls more
Eliminated class-associated tox issues
Short-term use of p38 for acute inflammation
overcomes tox concerns associated with long-term
treatment with p38 inhibitors for chronic
inflammatory conditions (e.g. Arthritis) I would say alot better for arthritis
Primarily focused on U.S and European markets for a strategic deal
Engaging early with select partners on POLB 001 ahead of initial LPS challenge data before
year end 2022 - maybe keep it quite when in talks !
Cutting Edge Data Analysis – Producing World Class Models - it will move us up
If only they said in that RNS results look on track very happy full results Q2- 2023
Why do you think the promised (POLB 001) results where helded back?
Hi cashintime - Hopefully tomorrow get us back up around 8p -
RYA not a fan of this stock but was thinking to take a small punt low 10 not 13 - is it worth it?
Looks like it might go over 9euros before yearend - definitely janurday. When was this over 9euros last?
No serious adverse events reported. POLB 001 was found to be safe and well tolerated - Thats not initial results we knew that before -
Come on jeremy you know some results right now and alot more in weeks ahead - why not update the market? Q2 for full results is fine but we need a update before then !!!
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: on 4oct
"We are continuing to expand our global patent protection for our growing pipeline of infectious disease products. We are delighted to receive confirmation from the US Patent and Trademarks office that the main claim is allowable, and we look forward to updating the market when we receive the formal patent grant in due course. Enhanced IP protection of our assets across key markets, such as the US, increases the overall value of these products to potential partners. This is particularly important as we move closer to the completion of our POLB 001 LPS human challenge trial, with initial results expected by year end 2022."
institutional investors looking shares discount? Hope not very nasty get there shares say 6p big news waiting 2023 - something not adding up
Desertstar - You have a point - On 8nov jeremy skilliington words - Hopefully we get a kind of an early an early day to read understanding as if they still be blinded but it give us an understanding. Last RNS give very little - they have to know more good or bad - we should be over 15p now if all is very good - moniman- I think i will bet wit you news about OO1 held back for the good